Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.52 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.49 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.49 |
| ▸ | DNPH1 | O43598 | 2/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.48 |
| ▸ | AHCY | P23526 | 2/20 | 0.48 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13396506 | 1.00 | P2RY12 (0.52) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL3317321 | 1.00 | P2RY12 (0.52) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL3320845 | 0.88 | P2RY12 (0.51) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL3320850 | 0.88 | P2RY12 (0.51) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL13396509 | 0.88 | P2RY12 (0.51) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL3320860 | 0.86 | P2RY12 (0.50) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL3314438 | 0.86 | P2RY12 (0.53) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL3314461 | 0.86 | P2RY12 (0.53) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL3314380 | 0.86 | P2RY12 (0.53) | P2RY12P2RY2P2RY1P2RY6DNPH1 | |
| SCHEMBL3316378 | 0.80 | AHCY (0.73) | P2RY2P2RY1DNPH1ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | P2RY12 782/4885P2RY2 1511/4885P2RY1 505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.